Regular ArticleTopoisomerase I inhibitors: selectivity and cellular resistance
References (120)
- et al.
Eukaryotic DNA topoisomerases I
Biochim Biophys Acta
(1995) Domains of human topoisomerase I and associated functions
Prog Nucleic Acids Res Mol Biol
(1998)- et al.
Structural insights into the function of type IB topoisomerases
Curr Opin Struct Biol
(1999) - et al.
Cellular resistance to topoisomerase I-targeted druugs: from drug uptake to cell death
Biochim Biophys Acta
(1998) - et al.
Analysis of camptothecin resistance in yeast: relevance to cancer therapy
Drug Resist Updates
(1998) - et al.
Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports
Ann Oncol
(1997) - et al.
Reconstitution of human topoisomerase I by fragment complementation
J Mol Biol
(1997) - et al.
Simian virus 40 large T antigen binds to topoisomerase I
Virology
(1996) - et al.
Identification of a nucleophilin binding site in human topoisomerase I
J Biol Chem
(1996) - et al.
Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin
J Biol Chem
(1991)
Characterization of camptothecin-resistant chinese hamster lung cells
Biochem Pharmacol
(1992)
Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation
Biochem Pharmacol
(1993)
Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines
Biomed Pharmacother
(1990)
Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I
J Biol Chem
(1997)
Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects
J Biol Chem
(1997)
Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct, 1, N6-ethenoadenine
J Biol Chem
(1998)
Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
J Biol Chem
(1997)
Mechanisms for the processing of a prozen topoisomerase-DNA conjugate by human cell-free extracts
J Biol Chem
(1998)
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis
J Biol Chem
(1999)
DNA topoisomerases
Annu Rev Biochem
(1996)
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
Biochim Biophys Acta
(1998)
DNA Topoisomerases: essential enzymes and lethal targets
Annu Rev Pharmacol Toxicol
(1994)
Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
Cancer Invest
(1994)
DNA topoisomerase I inhibitors and multidrug resistance
Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro
Nucleic Acids Res
(1999)
Processing of topoisomerase I cleavable complexes into DNA damage by transcription
Nucleic Acids Res
(1997)
Topoisomerase inhibitors: Why develop new ones
Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs
(1999)
Dual topoisomerase I and II inhibition by intoplicine (RP-60475) a new antitumor agent in early clinical trials
Mol Pharmacol
(1993)
DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin
Biochemistry
(1997)
Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons
J Med Chem
(1999)
Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents
Cancer Res
(1999)
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
J Natl Cancer Inst
(1994)
Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives
Biochemistry
(1995)
Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme
Cancer Res
(1998)
The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
Cancer Res
(1999)
The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
Naunyn Schmiedebergs Arch Pharmacol
(1997)
Mechanism of cross-resistane to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin
Cancer Res
(1992)
Establishement of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance
Cancer Res
(1990)
Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin)
J Surg Oncol
(1995)
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials
Cancer Chemother Pharmacol
(1994)
Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
Cancer Res
(1998)
Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
Cancer Res
(1996)
O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyltopotecan
Anticancer Drugs
(1998)
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea
Cancer Res
(1994)
Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
Cancer Chemother Pharmacol
(1995)
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
J Clin Invest
(1998)
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
J Clin Invest
(1998)
The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro
Jpn J Cancer Res
(1997)
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
Cancer Res
(1992)
Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis
Proc Natl Acad Sci USA
(1992)
Cited by (171)
The SOS response-associated peptidase (SRAP) domain of YedK catalyzes ring opening of abasic sites and reversal of its DNA–protein cross-link
2022, Journal of Biological ChemistryNew camptothecin derivatives for generalized oncological chemotherapy: Synthesis, stereochemistry and biology
2021, Bioorganic and Medicinal Chemistry LettersThe human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance
2019, Archives of Biochemistry and BiophysicsBenzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases
2019, European Journal of Medicinal ChemistryComparative studies of oxindolimine-metal complexes as inhibitors of human DNA topoisomerase IB
2018, Journal of Inorganic Biochemistry
Copyright © 1999 Harcourt Publishers Ltd. All rights reserved.